U.S., Jan. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07319871) titled 'A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer' on Dec. 22, 2025.
Brief Summary: The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.
Study Start Date: Dec. 30, 2025
Study Type: INTERVENTIONAL
Condition:
Prostatic Neoplasms
Intervention:
DRUG: Pasritamig
Pasritamig will be administered intravenously.
DRU...